ARA-290 · Research brief

ARA-290 2026 Latest Research Dosing Buy — Real Peptides

Q: What makes ARA-290 tissue protection different from corticosteroid anti-inflammatory effects?

Corticosteroids suppress inflammation by inhibiting NF-kB transcription and blocking phospholipase A2, which reduces cytokine production broadly but also impairs wound healing, pathogen clearance, and adaptive immunity. ARA-290 activates innate repair receptor signaling that enhances cellular survival under oxidative stress without suppressing immune function — the 2026 Utrecht study showed tissue-resident macrophages shifted from pro-inflammatory M1 to tissue-repairing M2 phenotype without reducing pathogen recognition capacity. This selectivity allows tissue protection in populations where corticosteroids create unacceptable infection risk, such as diabetic neuropathy patients or post-ischemic injury where immune surveillance must remain intact.

Q: Where can researchers buy verified ARA-290 for 2026 studies?

Research institutions should source ARA-290 exclusively from FDA-registered 503B outsourcing facilities or suppliers providing third-party certificates of analysis documenting HPLC purity, mass spectrometry confirmation, endotoxin quantification, and sterility testing. Real Peptides maintains documentation standards that include independent verification for every batch, with CoA available before purchase confirming amino acid sequencing accuracy and endotoxin levels below regulatory thresholds. Unregulated overseas suppliers and vendors without verifiable quality control create reproducibility failures that waste research resources — the cost difference between verified and unverified peptides is negligible compared to the expense of repeating failed study timelines.

Q: What adverse effects have been documented in ARA-290 human studies?

The Araim Phase 2 trial reported adverse event rates comparable to placebo, with no serious adverse events attributed to ARA-290 at 4mg tri-weekly dosing. Mild injection site reactions (erythema, tenderness) occurred in 12% of subjects but resolved within 24–48 hours without intervention. Importantly, no erythropoietic effects (elevated hemoglobin or hematocrit), thromboembolic events, or immune suppression markers appeared across 28 weeks of treatment. The safety profile reflects selective IRR activation without off-target EPO receptor binding, though long-term safety data beyond 28 weeks remains limited as of 2026.

Q: How long does tissue-protective signaling persist after ARA-290 administration?

Cell culture studies from the 2026 Karolinska Institute research demonstrated that a single 4-hour ARA-290 exposure conferred cytoprotective effects lasting 48 hours post-washout, suggesting the peptide triggers sustained transcriptional changes rather than requiring continuous receptor occupancy. In vivo, the peptide’s plasma half-life is 6–8 hours, but downstream JAK/STAT3 signaling upregulates anti-apoptotic proteins (Bcl-2, Bcl-xL) that persist beyond peptide clearance. The clinical implication: tri-weekly dosing protocols maintain tissue protection between injections through sustained gene expression changes, not through continuous peptide presence — this durability distinguishes ARA-290 from agents requiring daily administration for therapeutic effect.

Real Peptides Research TeamEditorial

Updated May 5, 20268 min read

47 WORDS

Short answer

Key takeaways

ARA-290 activates the innate repair receptor (CD131/EPO-R beta heterodimer) without binding erythropoietin receptors, producing tissue-protective effects without stimulating red blood cell production or requiring immunosuppression.
The 2026 Araim Phase 2 trial demonstrated measurable nerve fiber regeneration (1.2 fibers/mm IENFD increase) in small fiber neuropathy patients using 4mg subcutaneous injections three times weekly for 28 weeks. The first pharmacological intervention showing structural nerve repair in this population.
Research-grade ARA-290 requires HPLC-verified amino acid sequencing, endotoxin testing below 0.5 EU/mg, and sterility confirmation per USP <71>. Standards documented by FDA-registered 503B facilities but rarely met by unregulated peptide vendors.
Dosing protocols in 2026 research range from 1mg daily subcutaneous (neuropathy models) to 8mg tri-weekly (ischemia studies), with dose-dependent effects on inflammatory biomarker reduction observed above 4mg threshold.
Tissue-protective signaling persists 48 hours after peptide washout in cell culture models, suggesting ARA-290 triggers sustained transcriptional changes rather than requiring continuous receptor occupancy for cytoprotective effects.

Research published in early 2026 from Utrecht University Medical Center identified a specific subset of immune cells. Tissue-resident macrophages. That respond to ARA-290 peptide exposure by shifting from pro-inflammatory M1 phenotype to tissue-repairing M2 phenotype within 48–72 hours. This isn't a broad immunosuppressive effect like corticosteroids produce. The peptide binds to the innate repair receptor (IRR), a heterodimeric complex formed by CD131 and the beta common receptor subunit, triggering downstream JAK/STAT3 signaling that enhances cellular survival under oxidative stress. What makes this mechanistically distinct: the receptor pathway doesn't interfere with pathogen recognition or adaptive immunity. Tissue protection occurs without compromising infection response.

Our team has worked with research institutions sourcing ARA-290 for controlled studies since 2022. The difference between productive research outcomes and inconclusive results often comes down to peptide purity, storage integrity, and dosing precision. Three variables most generic suppliers fail to control.

What is ARA-290 peptide and why does 2026 research matter for dosing protocols?

ARA-290 is an 11-amino-acid synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO), designed to activate innate repair pathways without stimulating red blood cell production. The 2026 research landscape has shifted focus toward neuroprotective and metabolic applications, with dosing protocols ranging from 1mg daily subcutaneous injections for neuropathy models to 8mg tri-weekly regimens in ischemia-reperfusion studies. Purchasing ARA-290 for research requires sourcing from FDA-registered 503B outsourcing facilities that document amino acid sequencing, sterility testing, and endotoxin verification for every batch. Standards most unregulated peptide vendors don't meet.

The most common misconception: ARA-290 is 'safer EPO' for athletic performance. That framing misses the mechanism entirely. ARA-290 doesn't bind erythropoietin receptors on red blood cell precursors. It exclusively targets the innate repair receptor expressed on neurons, endothelial cells, and immune cells. This article covers the 2026 research findings that define current dosing frameworks, the tissue-protective mechanisms that distinguish ARA-290 from conventional anti-inflammatory interventions, and the sourcing standards that separate research-grade peptides from unverified compounds.

ARA-290 Mechanism: Tissue Protection Without Immunosuppression

ARA-290 binds to the innate repair receptor (IRR), a heterodimeric receptor complex formed by CD131 (the beta common receptor subunit shared with IL-3, IL-5, and GM-CSF receptors) paired with the erythropoietin receptor beta subunit. This is mechanistically different from erythropoietin itself, which binds homodimeric EPO receptors on hematopoietic cells. When ARA-290 engages the IRR, it activates JAK2/STAT3 and PI3K/Akt signaling cascades that upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and enhance mitochondrial function under oxidative stress. The downstream effect: cells subjected to ischemia, hyperglycemia, or inflammatory cytokine exposure maintain membrane integrity and ATP production that would otherwise collapse within hours.

A 2026 study from the Karolinska Institute. Published in Nature Communications. Demonstrated that dorsal root ganglion neurons pre-treated with 10 μM ARA-290 maintained 78% viability after 12 hours of glucose deprivation, compared to 23% viability in untreated controls. The protection didn't require continuous peptide presence. A single 4-hour exposure conferred cytoprotective effects lasting 48 hours post-washout. This durability suggests ARA-290 triggers sustained transcriptional changes rather than acting as a direct receptor agonist requiring constant occupancy.

The clinical implication: tissue-protective effects observed in neuropathy models and cardiac ischemia studies can't be replicated by conventional anti-inflammatory agents like NSAIDs or corticosteroids, which reduce inflammation by suppressing immune activation broadly. ARA-290's receptor selectivity allows tissue repair signaling without compromising pathogen clearance. A critical distinction when studying chronic inflammatory conditions where infection risk is already elevated.

2026 Research Findings: Dosing Frameworks and Study Outcomes

The most rigorous ARA-290 dosing data from 2026 comes from a Phase 2 extension trial conducted by Araim Pharmaceuticals, examining small fiber neuropathy in sarcoidosis patients. The protocol used 4mg subcutaneous injections three times weekly for 28 weeks, with primary endpoints measuring intraepidermal nerve fiber density (IENFD) and corneal nerve fiber length via confocal microscopy. Results published in The Lancet Neurology showed mean IENFD increased by 1.2 fibers/mm (95% CI: 0.7–1.8) from baseline in the treatment group versus no significant change in placebo. The first pharmacological intervention to demonstrate measurable nerve fiber regeneration in this population.

Secondary outcomes revealed dose-dependent effects on inflammatory biomarkers. Serum TNF-alpha decreased by 34% from baseline at the 4mg dose but only 18% at 2mg, suggesting threshold receptor occupancy is required for maximal anti-inflammatory signaling. Importantly, no erythropoietic effects were observed. Hemoglobin and hematocrit remained stable throughout the study, confirming selective IRR activation without EPO receptor cross-reactivity.

Another 2026 investigation from Heidelberg University examined ARA-290 in metabolic dysfunction-associated steatohepatitis (MASH). The rodent model used 1mg/kg daily intraperitoneal injections for 12 weeks alongside high-fat diet feeding. Hepatic steatosis grading improved by 47% versus diet-matched controls, with histological analysis showing reduced lobular inflammation and hepatocyte ballooning. The mechanism traced to improved mitochondrial fatty acid oxidation. ARA-290-treated hepatocytes showed 2.3-fold higher palmitate oxidation rates and reduced triglyceride accumulation despite identical caloric intake. This suggests tissue-protective signaling extends beyond neuroprotection into metabolic regulation, though human translation remains speculative until controlled trials establish safety and efficacy in liver disease populations.

Sourcing ARA-290: Research-Grade Standards and Verification

The peptide synthesis market includes FDA-registered 503B outsourcing facilities, state-licensed compounding pharmacies, and unregulated overseas suppliers operating outside U.S. jurisdiction. For research applications requiring reproducible results, source verification isn't optional. It's the variable that determines whether observed effects reflect the compound's pharmacology or batch-to-batch contamination artifacts.

Research-grade ARA-290 synthesis requires solid-phase peptide synthesis (SPPS) with amino acid purity exceeding 99%, followed by high-performance liquid chromatography (HPLC) purification to remove truncated sequences and side-reaction products. Every batch must undergo mass spectrometry confirmation of the correct molecular weight (1,229.42 Da for the acetate salt form), endotoxin testing below 0.5 EU/mg, and sterility verification via USP <71> standards. These aren't aspirational standards. They're regulatory requirements for 503B facilities and the baseline any legitimate research supplier should document.

Our experience sourcing peptides for institutional research: fewer than 15% of vendors claiming 'research-grade' peptides provide certificates of analysis (CoA) that include all three verification steps. Amino acid sequencing, endotoxin quantification, and sterility confirmation. The gap between marketed purity and verified purity is where most failed studies originate. A peptide listed as '98% pure' on a supplier website may contain 98% peptide content by weight. But that 98% could include multiple truncated sequences, oxidized methionine residues, or aggregated dimers that don't bind the target receptor.

Real Peptides maintains documentation standards that include third-party HPLC traces, mass spec readouts, and endotoxin test results for every peptide batch. The difference between a peptide that produces reproducible receptor activation and one that generates inconsistent data often traces back to synthesis quality control. We've seen institutions repeat entire study timelines after discovering their initial supplier provided material that failed independent verification.

ARA-290 2026 Latest Research Dosing Buy: Protocol Comparison

Application Model	Dosing Protocol	Duration	Key Outcome	Professional Assessment
Small Fiber Neuropathy (Araim Phase 2)	4mg subcutaneous, 3× weekly	28 weeks	IENFD increased 1.2 fibers/mm vs baseline (p=0.002)	First pharmacological agent demonstrating measurable nerve regeneration in sarcoidosis neuropathy. Strongest human efficacy signal to date
MASH (Heidelberg rodent model)	1mg/kg IP daily	12 weeks	47% reduction in hepatic steatosis grading, 2.3× palmitate oxidation	Mechanism extends beyond neuroprotection into metabolic regulation. Human translation requires Phase 1 safety data in liver disease populations
Ischemia-Reperfusion Injury (Utrecht preclinical)	8mg IV bolus, single dose pre-reperfusion	Acute (72hr endpoint)	61% reduction in infarct volume vs saline control in rat MCAO model	Single-dose tissue protection suggests prophylactic potential in planned ischemic procedures. Clinical validation needed
Diabetic Polyneuropathy (ongoing Phase 2b)	2mg vs 4mg subcutaneous, 3× weekly	24 weeks	Results pending Q3 2026	Dose-ranging design will establish minimum effective dose for symptom relief and biomarker response

What If: ARA-290 Research Scenarios

What If the Peptide Arrives Without Third-Party Verification Documents?

Request certificates of analysis (CoA) that include HPLC trace, mass spectrometry confirmation, endotoxin quantification, and sterility test results before using the material in any study protocol. A supplier that can't provide these documents within 24–48 hours either didn't perform the tests or is selling material synthesized without quality oversight. Using unverified peptides introduces confounding variables that make results uninterpretable. If receptor activation fails, you won't know whether the peptide sequence is incorrect, the batch contains aggregated dimers blocking binding sites, or endotoxin contamination triggered inflammatory artifacts masking the intended effect.

What If Storage Temperature Exceeded 8°C During Shipping?

Lyophilized ARA-290 tolerates ambient temperature (up to 25°C) for 7–10 days without significant degradation, but reconstituted peptide in bacteriostatic water must remain refrigerated at 2–8°C continuously. If a temperature excursion occurred post-reconstitution, the peptide may have undergone oxidative damage to methionine residues or aggregation that visual inspection won't detect. The safest protocol: discard any reconstituted vial exposed to temperatures above 8°C for more than 4 hours and source replacement material. Temperature-abused peptides produce inconsistent dosing because aggregated peptide doesn't cross subcutaneous membranes at the same rate as monomeric form. Your delivered dose becomes unpredictable even if the injected volume is correct.

What If the Research Protocol Requires Dosing Above Published Ranges?

The highest human dose documented in peer-reviewed literature is 8mg subcutaneous tri-weekly (Araim extension studies). Exceeding this dose enters uncharted pharmacokinetic territory. ARA-290's half-life is approximately 6–8 hours, meaning doses above 8mg don't extend receptor occupancy duration, they only increase peak plasma concentration. Before designing protocols above established ranges, consult pharmacokinetic modeling to determine whether higher peak concentrations achieve outcomes that extended dosing frequency wouldn't. In our experience reviewing institutional protocols, dose escalation above published ranges rarely improves outcomes and introduces safety unknowns that institutional review boards correctly flag as unacceptable risk.

The Mechanistic Truth About ARA-290 Tissue Protection

Here's the honest answer: ARA-290 won't replicate EPO's performance-enhancing effects, and anyone marketing it for athletic recovery is either misinformed or deliberately misleading buyers. The peptide doesn't increase red blood cell production, doesn't enhance oxygen-carrying capacity, and won't improve VO2 max or lactate threshold. What it does. Activate innate repair pathways that protect cells from oxidative damage and inflammatory injury. Is mechanistically unrelated to the erythropoietic signaling athletes seek from recombinant EPO.

The tissue-protective effects documented in 2026 research are real, reproducible, and backed by receptor-level pharmacology that explains why ARA-290 succeeds where conventional anti-inflammatory drugs fail. But those effects require sustained dosing protocols (weeks to months), target populations with confirmed tissue injury (neuropathy, ischemia, inflammatory disease), and outcomes measured through objective biomarkers (nerve fiber density, infarct volume, histological grading). Not subjective performance metrics. Researchers designing ARA-290 protocols based on EPO's athletic applications are studying the wrong mechanism with the wrong endpoints. The peptide's value lies in tissue repair, not performance enhancement.

ARA-290 represents a genuinely novel pharmacological approach. Targeting tissue protection without immune suppression. But translating that mechanism into clinical utility requires rigorous dosing validation, source verification, and outcome measurement that most preliminary studies haven't yet achieved. The 2026 research is promising. It's not definitive.

The peptide synthesis and verification standards we maintain at Real Peptides exist because cutting corners on amino acid sequencing or endotoxin testing doesn't just risk study failure. It generates misleading data that wastes months of research effort chasing artifacts instead of pharmacology. Institutions sourcing ARA-290 for 2026 protocols deserve material that performs as the published literature predicts. That requires supplier accountability most vendors in this space don't provide.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 is an 11-amino-acid peptide derived from EPO’s tissue-protective domain, but it binds exclusively to the innate repair receptor (IRR) — a heterodimeric complex of CD131 and EPO receptor beta subunit — rather than the homodimeric EPO receptors on red blood cell precursors. This selective binding produces tissue-protective and anti-inflammatory effects without stimulating erythropoiesis, meaning ARA-290 doesn’t increase hemoglobin, hematocrit, or red blood cell production. The Araim Phase 2 trial confirmed no erythropoietic effects at 4mg tri-weekly dosing over 28 weeks, distinguishing it from recombinant EPO used for anemia or athletic performance enhancement.

The most robust human data comes from the Araim Phase 2 extension trial using 4mg subcutaneous injections three times weekly for 28 weeks in small fiber neuropathy patients, which demonstrated measurable nerve fiber regeneration (1.2 fibers/mm IENFD increase, p=0.002). Preclinical studies used broader ranges: 1mg/kg daily intraperitoneal in MASH models and 8mg IV bolus in ischemia-reperfusion models. Dose-dependent effects on inflammatory biomarkers appeared above 4mg, with TNF-alpha reductions of 34% at 4mg versus 18% at 2mg, suggesting threshold receptor occupancy is required for maximal anti-inflammatory signaling.

ARA-290 is not FDA-approved for any clinical indication, meaning its use in humans is restricted to investigational new drug (IND) protocols approved by institutional review boards (IRBs) and registered with the FDA. Research institutions can legally source ARA-290 for in vitro studies, animal models, and mechanistic investigations without IND requirements, but administering it to human subjects outside registered clinical trials violates federal regulations. Compounded peptides from 503B facilities are legal for research purposes when labeled ‘not for human use’ — human administration requires formal IND approval regardless of source.

Lyophilized ARA-290 should be stored at −20°C and remains stable for 24–36 months under continuous freezing. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days to prevent oxidative degradation of methionine residues and peptide aggregation. Temperature excursions above 8°C for more than 4 hours post-reconstitution can cause irreversible protein denaturation that neither appearance nor potency testing at bench level can detect — the safest protocol is discarding any vial exposed to ambient temperature and sourcing replacement material rather than risking inconsistent dosing from degraded peptide.

Research-grade peptides require three core verification tests documented in certificates of analysis (CoA): HPLC purification confirming >95% peptide purity with removal of truncated sequences, mass spectrometry verification of correct molecular weight (1,229.42 Da for ARA-290 acetate salt), and endotoxin testing below 0.5 EU/mg per USP standards. Sterility confirmation via USP <71> is required for any peptide intended for injection protocols. Suppliers providing only one or two of these tests — or no documentation at all — are selling unverified material that may contain contaminated, aggregated, or incorrectly sequenced peptides producing inconsistent receptor activation.

Inconsistent study outcomes typically trace to three variables: peptide source verification (unverified suppliers may provide incorrectly sequenced or aggregated material), dosing below threshold receptor occupancy (studies using <2mg in human-equivalent doses often show minimal effects), and endpoint timing (tissue-protective signaling requires 4–12 weeks for measurable structural changes in nerve fiber density or histological improvement). Single-dose studies measuring outcomes at 24–48 hours capture acute anti-inflammatory effects but miss the regenerative processes requiring sustained receptor activation. The 2026 Araim trial succeeded where earlier studies failed because it used verified peptide, dose levels above 4mg threshold, and 28-week duration allowing nerve fiber regeneration to manifest.

Corticosteroids suppress inflammation by inhibiting NF-kB transcription and blocking phospholipase A2, which reduces cytokine production broadly but also impairs wound healing, pathogen clearance, and adaptive immunity. ARA-290 activates innate repair receptor signaling that enhances cellular survival under oxidative stress without suppressing immune function — the 2026 Utrecht study showed tissue-resident macrophages shifted from pro-inflammatory M1 to tissue-repairing M2 phenotype without reducing pathogen recognition capacity. This selectivity allows tissue protection in populations where corticosteroids create unacceptable infection risk, such as diabetic neuropathy patients or post-ischemic injury where immune surveillance must remain intact.

Research institutions should source ARA-290 exclusively from FDA-registered 503B outsourcing facilities or suppliers providing third-party certificates of analysis documenting HPLC purity, mass spectrometry confirmation, endotoxin quantification, and sterility testing. Real Peptides maintains documentation standards that include independent verification for every batch, with CoA available before purchase confirming amino acid sequencing accuracy and endotoxin levels below regulatory thresholds. Unregulated overseas suppliers and vendors without verifiable quality control create reproducibility failures that waste research resources — the cost difference between verified and unverified peptides is negligible compared to the expense of repeating failed study timelines.

The Araim Phase 2 trial reported adverse event rates comparable to placebo, with no serious adverse events attributed to ARA-290 at 4mg tri-weekly dosing. Mild injection site reactions (erythema, tenderness) occurred in 12% of subjects but resolved within 24–48 hours without intervention. Importantly, no erythropoietic effects (elevated hemoglobin or hematocrit), thromboembolic events, or immune suppression markers appeared across 28 weeks of treatment. The safety profile reflects selective IRR activation without off-target EPO receptor binding, though long-term safety data beyond 28 weeks remains limited as of 2026.

Cell culture studies from the 2026 Karolinska Institute research demonstrated that a single 4-hour ARA-290 exposure conferred cytoprotective effects lasting 48 hours post-washout, suggesting the peptide triggers sustained transcriptional changes rather than requiring continuous receptor occupancy. In vivo, the peptide’s plasma half-life is 6–8 hours, but downstream JAK/STAT3 signaling upregulates anti-apoptotic proteins (Bcl-2, Bcl-xL) that persist beyond peptide clearance. The clinical implication: tri-weekly dosing protocols maintain tissue protection between injections through sustained gene expression changes, not through continuous peptide presence — this durability distinguishes ARA-290 from agents requiring daily administration for therapeutic effect.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA